Intel stock extends gains after report of possible U.S. government stake
SAN DIEGO - Pharmaceutical and biotechnology services company VivoSim Labs, Inc. (NASDAQ:VIVS), currently valued at $4.84 million and considered undervalued according to InvestingPro Fair Value metrics, has appointed Tony Lialin as its Chief Commercial Officer, the company announced Thursday.
Lialin brings over 20 years of experience in commercializing life science platforms. At VivoSim Labs, he will lead go-to-market strategy, partnerships, and expansion of the company’s San Diego-based services that combine organ-specific 3D models with AI-driven analytics.
The company provides testing of drugs and drug candidates in three-dimensional human tissue models of liver and intestine. According to an internal analysis conducted by VivoSim Labs in July 2025, the global combined liver and gastrointestinal in-vitro models and toxicology services market generated $641 million in revenue in 2024, with the United States accounting for approximately $325 million. Despite challenging market conditions reflected in its -66.3% year-to-date return, the company has achieved impressive revenue growth of 94.52% in the last twelve months.
"Tony has a rare track record of turning disruptive science into durable commercial engines," said Keith Murphy, Executive Chairman of VivoSim Labs, in the press release.
The company noted that its services apply AI to quantify multi-parametric toxicity signatures across liver and intestinal organoid assays, which can help research teams prioritize candidates and plan studies.
VivoSim Labs anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration’s announcement on April 10, 2025, to refine animal testing requirements in favor of non-animal new approach methodologies.
The company operates from San Diego, California.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.